Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.61 |
| ▸ | VNN1 | O95497 | 2/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12541738 | 0.89 | GABRA5 (0.54) | CA1CA2GABRA5VNN1HDAC1 | |
| SCHEMBL11562643 | 0.88 | SMN1; SMN2 (0.60) | GABRA5VNN1HDAC1KDM4EL3MBTL1 | |
| SCHEMBL11567319 | 0.87 | ALDH1A1 (0.61) | CA1CA2GABRA5VNN1HDAC1 | |
| SCHEMBL22031931 | 0.87 | ALDH1A1 (0.56) | GABRA5VNN1HDAC1MAPK1KDM4E | |
| SCHEMBL14920974 | 0.86 | VNN1 (0.64) | CA1CA2GABRA5VNN1HDAC1 | |
| SCHEMBL22084214 | 0.86 | VNN1 (0.57) | CA1CA2GABRA5VNN1HDAC1 | |
| SCHEMBL6255906 | 0.86 | GABRA5 (0.53) | CA1CA2GABRA5VNN1HDAC1 | |
| SCHEMBL18511956 | 0.85 | GABRA5 (0.55) | CA1CA2GABRA5VNN1MAPK1 | |
| SCHEMBL26835967 | 0.85 | VNN1 (0.54) | VNN1HDAC1KDM4EHCAR3POLB | |
| SCHEMBL11563448 | 0.85 | HCAR3 (0.64) | VNN1HDAC1HCAR3POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| CN-112867712-B | Carboxamide as ubiquitin-specific protease inhibitor | 瓦洛早期发现股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3833661-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Valo Early Discovery, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| CN-112867712-A | Carboxamides as ubiquitin-specific protease inhibitors | 瓦洛早期发现股份有限公司 | 2021-05-28 | — | — | CN | disclosed |
| EP-3665169-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2020033707-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020033707-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2019032863-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-02-14 | — | — | WO | disclosed |
| WO-2019032863-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | CA1 1259/4885CA2 2429/4885GABRA5 1672/4885 |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | USP28, USP25, USP24 | CA1 1259/4885CA2 2429/4885GABRA5 1672/4885 |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | CA1 1259/4885CA2 2429/4885GABRA5 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.